Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy
Stock Information for Telomir Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.